Trial Outcomes & Findings for An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (NCT NCT04165135)

NCT ID: NCT04165135

Last Updated: 2024-07-12

Results Overview

Physical activity data was collected as daily active minutes measured on each valid day by wearing a fitness tracker continuously during study participation. Valid day = a day in which fitness tracker was worn for at least 10 hours. Daily active minutes were saved in two different sets of data collected by fitness tracker. For each set minutes were categorized by intensity of activity done. First set = minutes categorized according to time collected in each heart zone. Overall heart zone minutes = fat-burn minutes (heart rate: 50-69% of maximum) + cardio minutes (medium-to-high intensity exercise zone corresponds to heart rate: 70-84% of maximum) + peak minutes (high-intensity exercise zone, corresponds to heart rate \> 85% of maximum). Second set =minutes categorized according to active zones. Overall active zone minutes=lightly active minutes +fairly active minutes+very active minutes. Moderate-to-Vigorous Physical Activity (MVPA) minutes=Fairly active minutes+Very active minutes.

Recruitment status

COMPLETED

Target enrollment

103 participants

Primary outcome timeframe

From baseline to study completion (up to 18 months)

Results posted on

2024-07-12

Participant Flow

107 patients were screened, but 4 patients did not meet the eligibility criteria; in total, 103 participants were enrolled and started the study. Participants took part in this study at 17 investigative sites in Italy from 24 February 2020 up to 28 April 2022.

Participant milestones

Participant milestones
Measure
Standard of Care for Haemophilia A
Participants with severe or moderate Haemophilia A without inhibitors against Factor VIII, receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Overall Study
STARTED
103
Overall Study
COMPLETED
88
Overall Study
NOT COMPLETED
15

Reasons for withdrawal

Reasons for withdrawal
Measure
Standard of Care for Haemophilia A
Participants with severe or moderate Haemophilia A without inhibitors against Factor VIII, receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Overall Study
Protocol Violation
10
Overall Study
Participants withdrawal of consent
5

Baseline Characteristics

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Standard of Care for Haemophilia A
n=103 Participants
Participants with severe or moderate Haemophilia A without inhibitors against Factor VIII, receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Age, Continuous
28.3 years
STANDARD_DEVIATION 10.4 • n=99 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
Sex: Female, Male
Male
103 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
10 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
93 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Race/Ethnicity, Customized
White
99 Participants
n=99 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=99 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
1 Participants
n=99 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=99 Participants
Is Haemophilia A diagnosis confirmed
Yes
103 Participants
n=99 Participants
Is Haemophilia A diagnosis confirmed
No
0 Participants
n=99 Participants
Severity type
Moderate Haemophilia
6 Participants
n=99 Participants
Severity type
Severe Haemophilia
97 Participants
n=99 Participants

PRIMARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

Physical activity data was collected as daily active minutes measured on each valid day by wearing a fitness tracker continuously during study participation. Valid day = a day in which fitness tracker was worn for at least 10 hours. Daily active minutes were saved in two different sets of data collected by fitness tracker. For each set minutes were categorized by intensity of activity done. First set = minutes categorized according to time collected in each heart zone. Overall heart zone minutes = fat-burn minutes (heart rate: 50-69% of maximum) + cardio minutes (medium-to-high intensity exercise zone corresponds to heart rate: 70-84% of maximum) + peak minutes (high-intensity exercise zone, corresponds to heart rate \> 85% of maximum). Second set =minutes categorized according to active zones. Overall active zone minutes=lightly active minutes +fairly active minutes+very active minutes. Moderate-to-Vigorous Physical Activity (MVPA) minutes=Fairly active minutes+Very active minutes.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Number of Daily Active Minutes of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Heart Zone Minutes
53.2 number of daily active minutes
Interval -45.2 to 151.6
24.6 number of daily active minutes
Interval 10.9 to 38.3
39.2 number of daily active minutes
Interval 13.9 to 64.6
Mean Number of Daily Active Minutes of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Active Zone Minutes
226.5 number of daily active minutes
Interval 173.8 to 279.2
309.4 number of daily active minutes
Interval 264.6 to 354.1
284.1 number of daily active minutes
Interval 246.3 to 321.9
Mean Number of Daily Active Minutes of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
MVPA Minutes
13.8 number of daily active minutes
Interval 0.4 to 27.2
42.3 number of daily active minutes
Interval 23.5 to 61.0
28.6 number of daily active minutes
Interval 14.2 to 43.0

PRIMARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

Number of steps taken by the participants on each valid day were measured by wearing a fitness tracker continuously during study participation. Valid day was defined as a day in which fitness tracker was worn for at least 10 hours.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Number of Steps Taken Per Day by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
5402.4 number of steps per day
Interval 3150.3 to 7654.5
8788.3 number of steps per day
Interval 7233.9 to 10342.7
8279.8 number of steps per day
Interval 6419.9 to 10139.7

PRIMARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The MET is an objective measure of the ratio of the rate at which a person expends energy, relative to the mass of that person, while performing some specific physical activity compared to a reference. The METs were derived as: (amount of kilo calories (kcal) collected in the fat-burn, cardio, and peak minutes) / \[(sum of fat-burn, cardio and peak hours) \* weight of the participant in kilograms (kg)\].

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Metabolic Equivalent of Tasks (METs) Per Day Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
5.1 MET per day
Interval 3.7 to 6.5
5.3 MET per day
Interval 5.1 to 5.5
4.5 MET per day
Interval 4.1 to 4.9

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Number analyzed is the number of participants with data available for analysis.

The activity weekly rate was derived on a per participant basis as ratio between the number of times that the type of activity is reported on the fitness tracker (numerator) and the length of the observational period (i.e. end of study date - baseline date + 1) (denominator) and then multiplied by 7. The physical activities were categorized in the following groups: exercises at intervals, gym weights, running, swimming, tapis roulant, walk, general exercises: other types of physical activity identified by the fitness tracker that are not already included in the above-mentioned categories.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Tapis Roulant
0.06 number of times per week
Interval 0.04 to 0.07
0.11 number of times per week
Interval 0.0 to 0.23
0.05 number of times per week
Interval 0.02 to 0.08
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Exercises at Intervals
0.02 number of times per week
Interval 0.01 to 0.04
0.02 number of times per week
Interval 0.01 to 0.04
0.02 number of times per week
Interval 0.01 to 0.03
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
General
0.86 number of times per week
Interval 0.47 to 1.24
0.86 number of times per week
Interval 0.44 to 1.28
0.51 number of times per week
Interval 0.34 to 0.68
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Walk
0.53 number of times per week
Interval 0.05 to 1.01
1.30 number of times per week
Interval 0.97 to 1.63
0.88 number of times per week
Interval 0.44 to 1.33
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Gym Weights
0.03 number of times per week
Interval 0.0 to 0.06
0.63 number of times per week
Interval -1.93 to 3.2
0.13 number of times per week
Interval 0.03 to 0.23
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Running
0.06 number of times per week
Interval 0.02 to 0.1
0.12 number of times per week
Interval -0.02 to 0.26
0.18 number of times per week
Interval -0.01 to 0.37
Mean Rate of the Number of Times Engaging in Physical Activity Per Week by Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Swimming
0.03 number of times per week
Interval 0.0 to 0.06
0.06 number of times per week
Interval 0.0 to 0.12
0.03 number of times per week
Interval 0.02 to 0.04

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Number analyzed is the number of participants with data available for analysis.

The number of active minutes by intensity (lightly, fairly, and very active minutes) were obtained at the participant level on a per activity basis as the median of the values collected by the fitness tracker for each activity recorded during the observational period. In this analysis, the means and 95% confidence intervals were calculated using the median lightly active minutes by type of physical activity performed by participants with available data. The physical activities were categorized in the following groups: exercises at intervals, gym weights, running, swimming, tapis roulant, walk, general exercises: other types of physical activity identified by the fitness tracker that are not already included in the above-mentioned categories.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Running
0.1 lightly active minutes per activity
Interval -0.2 to 0.4
0.5 lightly active minutes per activity
Interval 0.0 to 1.1
0.3 lightly active minutes per activity
Interval -0.1 to 0.6
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Swimming
2.7 lightly active minutes per activity
Interval -6.7 to 12.1
2.8 lightly active minutes per activity
Interval 0.6 to 5.0
3.8 lightly active minutes per activity
Interval 0.4 to 7.1
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Tapis Roulant
0.5 lightly active minutes per activity
Interval -5.9 to 6.9
1.2 lightly active minutes per activity
Interval -1.5 to 3.9
5.0 lightly active minutes per activity
Interval -7.4 to 17.4
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Gym Weights
0.7 lightly active minutes per activity
Interval -1.2 to 2.6
3.7 lightly active minutes per activity
Interval -10.0 to 17.3
2.8 lightly active minutes per activity
Interval -0.1 to 5.7
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Exercises at Intervals
0.8 lightly active minutes per activity
Interval -0.8 to 2.3
0.0 lightly active minutes per activity
Interval 0.0 to 0.0
2.6 lightly active minutes per activity
Interval -0.9 to 6.2
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
General
11.2 lightly active minutes per activity
Interval 3.0 to 19.3
5.2 lightly active minutes per activity
Interval 3.1 to 7.3
5.8 lightly active minutes per activity
Interval 3.4 to 8.2
Mean Active Minutes by Intensity (Lightly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Walk
3.9 lightly active minutes per activity
Interval 1.5 to 6.4
3.3 lightly active minutes per activity
Interval 2.2 to 4.4
4.7 lightly active minutes per activity
Interval 2.7 to 6.7

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Number analyzed is the number of participants with data available for analysis.

The number of active minutes by intensity (lightly, fairly, and very active minutes) were obtained at the participant level on a per activity basis as the median of the values collected by the fitness tracker for each activity recorded during the observational period. In this analysis, the means and 95% confidence intervals were calculated using the median fairly active minutes by type of physical activity performed by participants with available data. The physical activities were categorized in the following groups: exercises at intervals, gym weights, running, swimming, tapis roulant, walk, general exercises: other types of physical activity identified by the fitness tracker that are not already included in the above-mentioned categories.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Swimming
1.7 fairly active minutes per activity
Interval -5.5 to 8.8
6.3 fairly active minutes per activity
Interval 2.5 to 10.1
4.5 fairly active minutes per activity
Interval -0.3 to 9.3
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Exercises at Intervals
1.3 fairly active minutes per activity
Interval -2.7 to 5.2
0.1 fairly active minutes per activity
Interval -0.1 to 0.3
0.0 fairly active minutes per activity
Interval 0.0 to 0.0
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
General
13.6 fairly active minutes per activity
Interval 5.6 to 21.6
11.3 fairly active minutes per activity
Interval 8.4 to 14.2
7.9 fairly active minutes per activity
Interval 3.9 to 11.8
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Walk
13.2 fairly active minutes per activity
Interval 8.0 to 18.3
9.8 fairly active minutes per activity
Interval 7.8 to 11.8
9.6 fairly active minutes per activity
Interval 7.8 to 11.3
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Running
0.0 fairly active minutes per activity
Interval 0.0 to 0.0
1.1 fairly active minutes per activity
Interval 0.2 to 2.0
0.3 fairly active minutes per activity
Interval -0.1 to 0.6
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Tapis Roulant
0.0 fairly active minutes per activity
Interval 0.0 to 0.0
2.3 fairly active minutes per activity
Interval 0.5 to 4.1
1.5 fairly active minutes per activity
Interval -2.2 to 5.2
Mean Active Minutes by Intensity (Fairly Active Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Gym Weights
0.2 fairly active minutes per activity
Interval -0.6 to 0.9
8.3 fairly active minutes per activity
Interval -21.3 to 38.0
8.7 fairly active minutes per activity
Interval 0.1 to 17.3

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Number analyzed is the number of participants with data available for analysis.

The number of active minutes by intensity (lightly, fairly, and very active minutes) were obtained at the participant level on a per activity basis as the median of the values collected by the fitness tracker for each activity recorded during the observational period. The MVPA minutes is the sum of fairly active and very active minutes. In this analysis, the means and 95% confidence intervals were calculated using the median MVPA minutes by type of physical activity performed by participants with available data. The physical activities were categorized in the following groups: exercises at intervals, gym weights, running, swimming, tapis roulant, walk, general exercises: other types of physical activity identified by the fitness tracker that are not already included in the above-mentioned categories.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Exercise at Intervals
4.3 MVPA minutes per activity
Interval -3.8 to 12.3
0.1 MVPA minutes per activity
Interval -0.1 to 0.3
0 MVPA minutes per activity
Interval 0.0 to 0.0
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Swimming
2.3 MVPA minutes per activity
Interval -7.7 to 12.4
14.4 MVPA minutes per activity
Interval 4.3 to 24.4
6.4 MVPA minutes per activity
Interval -0.9 to 13.6
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Tapis Roulant
0 MVPA minutes per activity
Interval 0.0 to 0.0
18.8 MVPA minutes per activity
Interval 0.5 to 37.1
17.5 MVPA minutes per activity
Interval -34.2 to 69.2
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Gym weights
5.0 MVPA minutes per activity
Interval -16.5 to 26.5
49.3 MVPA minutes per activity
Interval -56.8 to 155.5
29.6 MVPA minutes per activity
Interval -9.8 to 69.0
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
General
32.9 MVPA minutes per activity
Interval 9.5 to 56.3
34.3 MVPA minutes per activity
Interval 23.2 to 45.4
26.5 MVPA minutes per activity
Interval 14.3 to 38.6
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Walk
24.2 MVPA minutes per activity
Interval 15.3 to 33.0
33.7 MVPA minutes per activity
Interval 28.1 to 39.2
30.3 MVPA minutes per activity
Interval 20.7 to 39.8
Mean Active Minutes by Intensity (MVPA Minutes) for Each Type of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study
Running
4.3 MVPA minutes per activity
Interval -4.3 to 12.9
36.6 MVPA minutes per activity
Interval 21.4 to 51.8
12.8 MVPA minutes per activity
Interval -0.2 to 25.7

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

A participant was defined "adherent" to WHO guidelines according to the following algorithm: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes). A participant who was adherent to the WHO guidelines according to the above definition was defined as an "active participant", otherwise as a "sedentary participant".

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=22 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=26 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Percentage of Participants Who Were Adherent to World Health Organization (WHO) Global Recommendations on Physical Activity for Health Over the Course of the Study
Yes (Active Subjects)
0 percentage of participants
68.2 percentage of participants
42.3 percentage of participants
Percentage of Participants Who Were Adherent to World Health Organization (WHO) Global Recommendations on Physical Activity for Health Over the Course of the Study
No (Sedentary Subjects)
100 percentage of participants
31.8 percentage of participants
57.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Bleeds that occurred the same day but in different body site were counted separately.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=17 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=46 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=40 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study, Reported Via the ePRO Application
0 Bleeds
11 Participants
25 Participants
22 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study, Reported Via the ePRO Application
1 or More Bleeds
6 Participants
21 Participants
18 Participants

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months).

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

The assessment of bleeds was divided into spontaneous bleeds, traumatic bleeds, and bleeds related to procedure/surgery. Spontaneous bleeds = the occurrence of hemorrhage where neither the participant nor a caregiver could identify a reason. Traumatic bleeds = hemorrhage occurring secondary to an event such as trauma, "strenuous" activity, or "overuse". Bleeds related to procedure/surgery = such as hematomas resulting from any surgeries or invasive procedures.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=17 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=46 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=40 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Spontaneous Bleed · 1 or More Bleeds
2 Participants
10 Participants
7 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Traumatic Bleed · 0 Bleeds
14 Participants
28 Participants
26 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Traumatic Bleed · 1 or More Bleeds
3 Participants
18 Participants
14 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Bleeds Related to Procedures/Surgeries · 0 Bleeds
17 Participants
46 Participants
39 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Bleeds Related to Procedures/Surgeries · 1 or More Bleeds
0 Participants
0 Participants
1 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Different Types of Bleeds (Spontaneous, Traumatic and Procedure/Surgery Related), Reported Via the ePRO Application
Spontaneous Bleed · 0 Bleeds
15 Participants
36 Participants
33 Participants

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occured from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Sites of bleeds were defined as urine, faeces, and vomit (three sites grouped together), joint, muscle, and other bleeds.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=17 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=46 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
n=40 Participants
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Urine, Faeces, and Vomit Bleeds · 0 Bleeds
17 Participants
45 Participants
36 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Urine, Faeces, and Vomit Bleeds · 1 or More Bleeds
0 Participants
1 Participants
4 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Joint Bleeds · 0 Bleeds
13 Participants
31 Participants
26 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Joint Bleeds · 1 or More Bleeds
4 Participants
15 Participants
14 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Muscle Bleeds · 0 Bleeds
15 Participants
40 Participants
36 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Muscle Bleeds · 1 or More Bleeds
2 Participants
6 Participants
4 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Other Bleeds · 0 Bleeds
15 Participants
40 Participants
34 Participants
Number of Participants by the Presence of Bleeds (0 vs. ≥1 Bleeds) Over the Course of the Study According to the Bleed Sites (Urine, Feces, and Vomit, Joint, Muscle, and Other Bleeds), Reported Via the ePRO Application
Other Bleeds · 1 or More Bleeds
2 Participants
6 Participants
6 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

The following types of regimens used to treat haemophilia A are reported here: on-demand (to stop bleeding) and prophylaxis (regular infusions of clotting factor to prevent bleeds). Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=103 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
On Demand for Haemophilia
1 Participants
Number of Participants by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis For Haemophilia
102 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=103 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Octocog Alfa
39 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Efmoroctocog alfa
25 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Moroctocog Alfa
8 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Turoctocog Alfa
8 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Lonoctocog Alfa
6 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Rurioctocog Alfa Pegol
6 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Damoctocog Alfa Pegol
3 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Simoctocog Alfa
3 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Turoctocog Alfa Pegol
3 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Factor VIII (Antihaemophilic Factor)
2 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Factor VIII, Recombinant
1 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Emicizumab
17 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Desmopressin
1 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Tranexamic Acid
2 Participants
Number of Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
On Demand for Haemophilia: Octocog Alfa
1 Participants

SECONDARY outcome

Timeframe: From baseline to the time of switch to a new therapy (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=103 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Turoctocog Alfa Pegol
7 Participants
Number of Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Damoctocog Alfa Pegol
3 Participants
Number of Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Rurioctocog Alfa Pegol
3 Participants
Number of Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Emicizumab
8 Participants

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint.

An event was considered a treated bleed if coagulation factors were administered to treat signs or symptoms of bleeding (e.g., pain, swelling, etc.).

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=129 Bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Treated Bleeds Over the Course of the Study
94 number of treated bleeds

SECONDARY outcome

Timeframe: From baseline to whenever bleeding occurred (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint.

An event was considered a treated bleed if coagulation factors were administered to treat signs or symptoms of bleeding (e.g., pain, swelling, etc.).

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=94 Treated bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Bleeds Treated With Each Type of Treatment for Bleeding (Haemostatic Treatment, Treatment for Pain)
Treatment for Pain
1 number of treated bleeds
Number of Bleeds Treated With Each Type of Treatment for Bleeding (Haemostatic Treatment, Treatment for Pain)
Haemostatic Treatment
93 number of treated bleeds

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=94 Treated bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Duration of Treatment for Bleeding Over the Course of the Study
2.0 days
Interval 1.0 to 18.0

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint.

Number of bleeds treated by intravenous, subcutaneous, intramuscular, nasal, ophthalmic, oral, rectal, and other routes of administration are reported here.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=94 Treated bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Intravenous
90 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Subcutaneous
0 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Oral
4 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Intramuscular
0 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Nasal
0 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Ophthalmic
0 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Rectal
0 number of treated bleeds
Number of Bleeds Treated With Each Route of Administration Over the Course of the Study
Others
0 number of treated bleeds

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=129 Bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Bleeds Which Needed to Receive a Transfusion
0 number of bleeds

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=129 Bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Bleeds Which Needed to Administer an Additional Hemostatic Therapy
4 number of bleeds

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of bleeds analyzed=number of bleeds during analysis at given timepoint.

The adherence to the treatment regimen for haemophilia A was analyzed as the number of bleeds with an answer equal to "Yes" and "My therapeutic plan does not include any treatment in the last week" in the week preceding the bleeding.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=129 Bleeds
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Bleeds With Adherence to Treatment Regimen for Haemophilia A in the Week Preceding the Bleeding
77 Number of bleeds

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. A total of 4 participants had missing data and were excluded from this analysis

The adherence to the treatment regimen for haemophilia A was analyzed as the number of participants with \<80% or ≥80% of weeks on study with "Yes" and "My therapeutic plan does not include any treatment in the last week" over the total number of weeks reported via the ePRO. Missing data from some weeks was treated as "No". The total number of weeks on study for each participant was derived as (End of study date - Baseline date + 1) / 7.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=99 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants Who Were Adherent to the Treatment Regimen for Haemophilia A Over the Course of the Study by Adherence Category (<80% vs. ≥80% of Study Weeks)
Adherence <80% of Weeks
72 Participants
Number of Participants Who Were Adherent to the Treatment Regimen for Haemophilia A Over the Course of the Study by Adherence Category (<80% vs. ≥80% of Study Weeks)
Adherence ≥80% of Weeks
27 Participants

SECONDARY outcome

Timeframe: Baseline and every 3 months until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=103 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Etoricoxib
5 Participants
Number of Participants by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Paracetamol
4 Participants

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

Participants reported the intensity of pain in their main joints (elbow, knee, ankle) by marking on a visual analogue scale (VAS), a horizontal line 100 millimeters (mm) in length, anchored by word descriptors at each end, where the left extreme means "No pain = 0" while the right extreme means "Worst Pain Imaginable = 100". The VAS score is the distance (in mm) from the left end of the line to the point where the participant marks crossed the line. VAS scale was submitted to the participants every month during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=100 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 7
19.89 scores on a scale
Interval 14.19 to 25.59
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 8
17.85 scores on a scale
Interval 12.17 to 23.54
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 9
17.58 scores on a scale
Interval 11.8 to 23.36
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 10
18.20 scores on a scale
Interval 12.75 to 23.65
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Baseline
14.24 scores on a scale
Interval 10.09 to 18.39
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 1
18.38 scores on a scale
Interval 13.5 to 23.26
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 2
16.91 scores on a scale
Interval 11.97 to 21.85
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 3
17.53 scores on a scale
Interval 12.77 to 22.28
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 4
21.77 scores on a scale
Interval 16.1 to 27.44
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 5
18.76 scores on a scale
Interval 13.37 to 24.15
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 6
18.98 scores on a scale
Interval 13.99 to 23.97
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 11
20.26 scores on a scale
Interval 14.31 to 26.22
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 12
19.85 scores on a scale
Interval 13.88 to 25.82
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 13
29.50 scores on a scale
Interval -18.53 to 77.53
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 14
21.40 scores on a scale
Interval -2.85 to 45.65
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 15
20.75 scores on a scale
Interval -2.97 to 44.47
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 16
12.50 scores on a scale
Interval -146.33 to 171.33
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 17
15 scores on a scale
Interval -175.59 to 205.59
Pain Intensity, as Reported by Participants Using a Visual Analogue Scale
Month 18
1.00 scores on a scale
Interval -11.71 to 13.71

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L includes five levels of severity in each of the five EuroQol-5D dimensions and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each dimension having 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state. EQ-5D-5L questionnaire was submitted to the participants every 3 month from baseline during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=100 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 1
0.89 scores on a scale
Due to low number of participants, upper and lower limits of 95% CI could not be calculated.
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 3
0.90 scores on a scale
Interval 0.88 to 0.93
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 6
0.90 scores on a scale
Interval 0.88 to 0.92
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 10
0.80 scores on a scale
Interval 0.62 to 0.97
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Baseline
0.93 scores on a scale
Interval 0.91 to 0.94
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 4
0.94 scores on a scale
Interval 0.9 to 0.98
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 5
0.94 scores on a scale
Interval 0.11 to 1.76
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 7
0.92 scores on a scale
Interval 0.83 to 1.01
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 8
0.93 scores on a scale
Interval 0.9 to 0.95
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 9
0.88 scores on a scale
Interval 0.85 to 0.91
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 11
0.90 scores on a scale
Interval 0.87 to 0.92
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 12
0.92 scores on a scale
Interval 0.89 to 0.96
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 13
0.62 scores on a scale
Due to low number of participants, upper and lower limits of 95% CI could not be calculated.
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 14
0.86 scores on a scale
Interval 0.79 to 0.93
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 15
0.85 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 17
0.90 scores on a scale
Interval -0.33 to 2.14
Health-Related Quality of Life (HRQoL): European Quality of Life-5 Dimensions (EQ-5D-5L) Health State Utility Index Score Over Time
Month 18
0.92 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and the other section is an evaluation of the overall health status using VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS from 0 to 100 on how good or bad their health is at assessment; 0 means the worst health imaginable, and 100 means the best health imaginable.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=100 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 5
83.5 scores on a scale
Interval -75.3 to 242.3
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 6
75.8 scores on a scale
Interval 70.1 to 81.4
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 8
78.4 scores on a scale
Interval 71.3 to 85.6
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 9
73.3 scores on a scale
Interval 63.1 to 83.5
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 12
69.6 scores on a scale
Interval 55.5 to 83.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 13
65 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Baseline
81.9 scores on a scale
Interval 77.8 to 86.0
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 1
81.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 3
80.6 scores on a scale
Interval 76.2 to 85.0
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 4
86.0 scores on a scale
Interval 74.4 to 97.6
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 7
64 scores on a scale
Interval 29.6 to 98.4
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 10
72.5 scores on a scale
Interval 40.0 to 105.0
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 11
75.3 scores on a scale
Interval 68.6 to 82.1
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 14
83.3 scores on a scale
Interval 56.7 to 109.8
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 15
75 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 17
85 scores on a scale
Interval -105.6 to 275.6
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score
Month 18
97 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

The HJHS is an instrument developed to measure joint health status and to identify early signs of joint disease in children. This tool assesses joints most commonly affected by bleeding (knees, ankles, and elbows). Each of the 6 joints is assessed across 8 domains (Swelling, Duration of Swelling, Atrophy, Crepitus, Flexion Loss, Extension Loss, Pain, and Strength), and a Total Score is calculated as the sum of all joint domain scores. The score range is from 0 to 124 points (a score of 0 indicates no joint damage). A higher score indicates higher joint damage.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=102 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Haemophilia Joint Health Score (HJHS) Total Score Over Time
Baseline
10 scores on a scale
Interval 7.2 to 12.7
Haemophilia Joint Health Score (HJHS) Total Score Over Time
Month 6
13.7 scores on a scale
Interval 3.5 to 23.8
Haemophilia Joint Health Score (HJHS) Total Score Over Time
Month 12
12.5 scores on a scale
Interval 7.4 to 17.6

SECONDARY outcome

Timeframe: Baseline, Months 3, 6, 9, 12, 15 and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=101 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Mean Body Mass Index (BMI) Over Time
Baseline
23.34 kilogram per square meter (kg/m2)
Interval 22.64 to 24.05
Mean Body Mass Index (BMI) Over Time
Month 3
23.56 kilogram per square meter (kg/m2)
Interval 22.26 to 24.86
Mean Body Mass Index (BMI) Over Time
Month 6
23.42 kilogram per square meter (kg/m2)
Interval 22.02 to 24.82
Mean Body Mass Index (BMI) Over Time
Month 9
23.76 kilogram per square meter (kg/m2)
Interval 21.31 to 26.21
Mean Body Mass Index (BMI) Over Time
Month 12
22.98 kilogram per square meter (kg/m2)
Interval 21.88 to 24.07

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The number of days away from school or work (participant) was analyzed every month as a continuous variable. The yearly rate was derived on a per participant basis as the proportion between the total number of days away from school and/or work and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=96 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Days Away From School or Work for Participants
0 days/year
Interval 0.0 to 57.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The number of days away from work was analyzed every month as a continuous variable. The yearly rate was derived on a per participant (for parents and caregivers) basis as the proportion between the total number of days away from work and duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=96 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Days Away From Work for Parent/Caregiver
0 days/year
Interval 0.0 to 57.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The yearly rate was derived on a per participant basis as the proportion between the total number of hospitalization days and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=96 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Hospitalization Days
0.0 days/year
Interval 0.0 to 15.6

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=8 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Age of Possible Early Retirement of Caregiver, as Reported by Caregivers in a Questionnaire
57.8 years
Interval 38.1 to 77.4

SECONDARY outcome

Timeframe: From baseline up to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants who were adherent to the WHO guidelines for physical activity according to the below definition were defined as an "active participant", otherwise as a "sedentary participant". A participant was defined "adherent" to WHO guidelines according to the following algorithm: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes). The participants were classified as 'Active' or 'Sedentary' based on data collected from baseline till the end of the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=97 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Active Versus Sedentary Participants by the Severity (Moderate or Severe) of Haemophilia A
Sedentary Participants
3 Participants
54 Participants
Number of Active Versus Sedentary Participants by the Severity (Moderate or Severe) of Haemophilia A
Active Participants
3 Participants
34 Participants
Number of Active Versus Sedentary Participants by the Severity (Moderate or Severe) of Haemophilia A
Unknown
0 Participants
9 Participants

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The annualized bleeding rate was derived as follows: total number of bleeds/total follow-up (person-year), where the individual's study duration was given by (\[end of study date-baseline date +1\] divided by 365.25). ABR was reported in active and sedentary participants. A participant who was adherent to the WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes).

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Annualized Bleeding Rates (ABR) in Active Versus Sedentary Participants
1.945 rate of bleeds per person-year
Interval 1.481 to 2.509
1.384 rate of bleeds per person-year
Interval 0.974 to 1.907

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoint.

Participants reported intensity of pain in their main joints (elbow, knee, ankle) by marking on a VAS, a horizontal line 100 mm in length, anchored by word descriptors at each end, where the left extreme means "No pain = 0" while right extreme means "Worst Pain Imaginable = 100". VAS score is the distance (in mm) from left end of the line to the point where participant marks crossed the line. A participant who was adherent to WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day ≥60 minutes. 18-50 years old: Fairly active (moderate) minutes per week ≥150 minutes or Very active (vigorous) minutes per week ≥75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes). VAS scale was submitted to the participants every month during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 1
21.29 scores on a scale
Interval 11.95 to 30.63
15.73 scores on a scale
Interval 7.03 to 24.43
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 2
18.32 scores on a scale
Interval 10.83 to 25.81
16.75 scores on a scale
Interval 6.89 to 26.61
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 3
22.80 scores on a scale
Interval 14.38 to 31.22
17.17 scores on a scale
Interval 7.82 to 26.53
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 4
27.56 scores on a scale
Interval 17.11 to 38.01
24.22 scores on a scale
Interval 11.83 to 36.61
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 5
23.28 scores on a scale
Interval 13.28 to 33.28
20 scores on a scale
Interval 8.69 to 31.31
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 7
22.52 scores on a scale
Interval 12.16 to 32.89
20.78 scores on a scale
Interval 10.9 to 30.67
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 10
20.16 scores on a scale
Interval 8.92 to 31.4
20.98 scores on a scale
Interval 11.65 to 30.3
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 11
20.72 scores on a scale
Interval 10.23 to 31.21
21.09 scores on a scale
Interval 11.97 to 30.21
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 12
22.68 scores on a scale
Interval 10.94 to 34.43
25 scores on a scale
Interval 12.11 to 37.89
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 13
7.50 scores on a scale
Interval -87.8 to 102.8
51.50 scores on a scale
Interval -183.56 to 286.56
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 14
8.33 scores on a scale
Interval -10.64 to 27.31
33 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 16
12.50 scores on a scale
Interval -146.33 to 171.33
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 18
1 scores on a scale
Interval -11.71 to 13.71
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Baseline
17.86 scores on a scale
Interval 8.84 to 26.87
14.12 scores on a scale
Interval 4.8 to 23.44
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 6
24.09 scores on a scale
Interval 13.13 to 35.04
20.67 scores on a scale
Interval 10.73 to 30.61
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 8
22.02 scores on a scale
Interval 10.81 to 33.23
19.98 scores on a scale
Interval 8.34 to 31.61
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 9
17.80 scores on a scale
Interval 7.43 to 28.18
24.81 scores on a scale
Interval 13.64 to 35.97
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 15
16.67 scores on a scale
Interval -21.28 to 54.61
33 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Pain Intensity in Active Versus Sedentary Participants, as Reported by Participants Using a Visual Analogue Scale
Month 17
15 scores on a scale
Interval -175.59 to 205.59

SECONDARY outcome

Timeframe: Baseline and every 3 months until study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

A participant who was adherent to the WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes). Participants can have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Active Versus Sedentary Participants by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Etoricoxib
2 Participants
2 Participants
Number of Active Versus Sedentary Participants by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Paracetamol
1 Participants
2 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The following types of regimens used to treat haemophilia A are reported here: on-demand (to stop bleeding) and prophylaxis (regular infusions of clotting factor to prevent bleeds). A participant who was adherent to the WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes). Participants can have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Active Versus Sedentary Participants by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia
28 Participants
25 Participants
Number of Active Versus Sedentary Participants by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
On Demand for Haemophilia
0 Participants
1 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

A participant who was adherent to the WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes).

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Octocog Alfa
8 Participants
10 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Efmoroctocog Alfa
8 Participants
7 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Moroctocog Alfa
3 Participants
2 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Rurioctocog Alfa Pegol
2 Participants
1 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Turoctocog Alfa Pegol
1 Participants
2 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Turoctocog Alfa
1 Participants
3 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Lonoctocog Alfa
3 Participants
0 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Simoctocog Alfa
3 Participants
0 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Damoctocog Alfa Pegol
0 Participants
1 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Factor VIII (Antihemophilic Factor)
0 Participants
1 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Emicizumab
6 Participants
3 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia: Tranexamic Acid
1 Participants
1 Participants
Number of Active Versus Sedentary Participants by the Product Used for Treatment of Haemophilia A Over the Course of the Study
On Demand for Haemophilia: Octocog Alfa
0 Participants
1 Participants

SECONDARY outcome

Timeframe: From baseline to the time of switch to a new therapy (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

A participant who was adherent to the WHO guidelines for physical activity according to the below definition was defined as an "active participant", otherwise as a "sedentary participant". WHO guidelines for adherence: 12-17 years old: MVPA minutes per day \>= 60 minutes. 18-50 years old: Fairly active (moderate) minutes per week \>= 150 minutes or Very active (vigorous) minutes per week \>= 75 minutes or an equivalent combination of fairly and very active minutes (i.e., considering 1 fairly active minute as 0.5 very active minutes).

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Active Versus Sedentary Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Turoctocog Alfa Pegol
1 Participants
4 Participants
Number of Active Versus Sedentary Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Damoctocog Alfa Pegol
1 Participants
1 Participants
Number of Active Versus Sedentary Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Rurioctocog Alfa Pegol
1 Participants
0 Participants
Number of Active Versus Sedentary Participants Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Emicizumab
5 Participants
0 Participants

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

EQ-5D-5L is a standardized measure of health status developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L includes five levels of severity in each of five EuroQol-5D dimensions and EQ VAS. Descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each dimension having 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Response options are measured with a 5-point Likert scale. 5D-5L systems are converted into a single index utility score between 0-1, where higher score indicates a better health state and lower score indicate worse health state. A participant who was adherent to WHO guidelines for physical activity was defined as an "active participant", otherwise as a "sedentary participant". EQ-5D-5L questionnaire was submitted to participants every 3 month from baseline during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=25 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Baseline
0.90 scores on a scale
Interval 0.86 to 0.94
0.93 scores on a scale
Interval 0.9 to 0.95
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 1
0.89 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 7
0.87 scores on a scale
Interval 0.74 to 0.99
0.94 scores on a scale
Interval 0.11 to 1.76
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 8
0.9 scores on a scale
Interval 0.86 to 0.94
0.91 scores on a scale
Interval 0.87 to 0.95
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 9
0.85 scores on a scale
Interval 0.8 to 0.91
0.88 scores on a scale
Interval 0.81 to 0.94
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 11
0.89 scores on a scale
Interval 0.85 to 0.94
0.89 scores on a scale
Interval 0.85 to 0.93
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 14
0.89 scores on a scale
Interval 0.38 to 1.39
0.86 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated..
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 3
0.89 scores on a scale
Interval 0.84 to 0.93
0.90 scores on a scale
Interval 0.86 to 0.94
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 4
0.95 scores on a scale
Interval 0.33 to 1.57
1 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 6
0.87 scores on a scale
Interval 0.81 to 0.92
0.90 scores on a scale
Interval 0.87 to 0.93
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 12
0.86 scores on a scale
Interval 0.74 to 0.98
0.97 scores on a scale
Interval 0.88 to 1.06
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 13
0.62 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 15
0.85 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 17
0.90 scores on a scale
Interval -0.33 to 2.14
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time for Active Versus Sedentary Participants
Month 18
0.92 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities pain/discomfort, anxiety/depression) and the other section is an evaluation of the overall health status using VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS from 0 to 100 on how good or bad their health is at assessment; 0 means the worst health imaginable, and 100 means the best health imaginable. A participant who was adherent to the WHO guidelines for physical activity was defined as an "active participant", otherwise as a "sedentary participant".

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=25 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 8
80.2 scores on a scale
Interval 70.2 to 90.2
79.1 scores on a scale
Interval 66.8 to 91.5
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 9
70.7 scores on a scale
Interval 53.0 to 88.4
67.0 scores on a scale
Interval 44.1 to 89.9
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 11
81.7 scores on a scale
Interval 74.5 to 88.9
66.7 scores on a scale
Interval 53.7 to 79.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 13
65.0 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Baseline
79.9 scores on a scale
Interval 72.9 to 86.8
78.1 scores on a scale
Interval 66.7 to 89.5
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 7
62.5 scores on a scale
Interval 30.7 to 94.3
55.0 scores on a scale
Interval -389.7 to 499.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 14
97.5 scores on a scale
Interval 65.7 to 129.3
67.0 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 1
81.0 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 3
76.9 scores on a scale
Interval 68.7 to 85.1
81.8 scores on a scale
Interval 74.3 to 89.3
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 4
80.0 scores on a scale
Interval -174.1 to 334.1
97.0 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 6
73.1 scores on a scale
Interval 62.8 to 83.4
76.1 scores on a scale
Interval 67.3 to 84.9
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 12
47.8 scores on a scale
Interval 7.2 to 88.4
89.3 scores on a scale
Interval 79.5 to 99.0
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 15
75 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 17
85.0 scores on a scale
Interval -105.6 to 275.6
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Active Versus Sedentary Participants
Month 18
97 scores on a scale
Since only one participants was evaluated upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study. Number analyzed is the number of participants with data available for analysis at given timepoint.

The HJHS is an instrument developed to measure joint health status and to identify early signs of joint disease in children. This tool assesses joints most commonly affected by bleeding (knees, ankles, and elbows). Each of the 6 joints is assessed across 8 domains (Swelling, Duration of Swelling, Atrophy, Crepitus, Flexion Loss, Extension Loss, Pain, and Strength), and a Total Score is calculated as the sum of all joint domain scores. The score range is from 0 to 124 points (a score of 0 indicates no joint damage). A higher score indicates higher joint damage.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
HJHS Total Score for Active Versus Sedentary Participants Over Time
Baseline
11.8 scores on a scale
Interval 5.1 to 18.4
12.1 scores on a scale
Interval 6.2 to 18.0
HJHS Total Score for Active Versus Sedentary Participants Over Time
Month 6
29.3 scores on a scale
Interval -7.3 to 66.0
8.7 scores on a scale
Interval 3.0 to 14.4
HJHS Total Score for Active Versus Sedentary Participants Over Time
Month 12
17.3 scores on a scale
Interval 4.8 to 29.9
15.0 scores on a scale
Interval 5.4 to 24.6

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The number of days away from school or work (participant) was analyzed every month as a continuous variable. The yearly rate was derived on a per participant basis as the proportion between the total number of days away from school and/or work and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Number of Days Away From School/Work for Active Versus Sedentary Participants
0.0 days/year
Interval 0.0 to 57.0
0.0 days/year
Interval 0.0 to 12.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The number of days away from work was analyzed every month as a continuous variable. The yearly rate was derived on a per participant (for parents/caregivers) basis as the proportion between the total number of days away from work and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Number of Days Away From Work for Active Versus Sedentary Participant's Parents or Caregivers
0.0 days/year
Interval 0.0 to 57.0
0.0 days/year
Interval 0.0 to 4.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: Evaluable population included all enrolled participants with at least 6 valid months of physical activity evaluations during the study.

The yearly rate was derived on a per participant basis as the proportion between the total number of hospitalization days and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=28 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=26 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Number of Hospitalization Days for Active Versus Sedentary Participants
0 days
Interval 0.0 to 5.0
0 days
Interval 0.0 to 0.9

SECONDARY outcome

Timeframe: Baseline and whenever bleeding occurred from study initiation to completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number of participants analyzed is the number of participants with available physical activities data in ITT population for sedentary and active participants.

The annualized bleeding rate was derived as follows: total number of bleeds/total follow-up (person-year), where the individual's study duration was given by (\[end of study date-baseline date +1\] divided by 365.25). A participant who was adherent to the WHO guidelines for physical activity was defined as an "active participant", otherwise as a "sedentary participant". Participants were classified for disease severity at baseline: severe (Factor VIII activity \<1%) or moderate (Factor VIII activity between ≥1% and ≤2%) haemophilia A.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=57 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=37 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Annualized Bleeding Rates in Active Versus Sedentary Participants by the Severity (Moderate Versus Severe) of Haemophilia A
Moderate Haemophilia
0.368 rate of bleeds per person-year
Interval 0.009 to 2.049
2.536 rate of bleeds per person-year
Interval 1.095 to 4.998
Annualized Bleeding Rates in Active Versus Sedentary Participants by the Severity (Moderate Versus Severe) of Haemophilia A
Severe Haemophilia
1.517 rate of bleeds per person-year
Interval 1.212 to 1.876
1.035 rate of bleeds per person-year
Interval 0.717 to 1.446

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoint.

Participants reported the intensity of pain in their main joints (elbow, knee, ankle) by marking on a VAS, a horizontal line 100 mm in length, anchored by word descriptors at each end, where the left extreme means "No pain = 0" while the right extreme means "Worst Pain Imaginable = 100". The VAS score is the distance (in mm) from the left end of the line to the point where the participant marks crossed the line. VAS scale was submitted to the participants every month during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=94 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 14
21.40 scores on a scale
Interval -2.85 to 45.65
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 17
15.00 scores on a scale
Interval -175.59 to 205.59
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 18
1.00 scores on a scale
Interval -11.71 to 13.71
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Baseline
23.33 scores on a scale
Interval -5.34 to 52.01
13.66 scores on a scale
Interval 9.46 to 17.86
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 1
23.67 scores on a scale
Interval -8.87 to 56.2
17.96 scores on a scale
Interval 13.03 to 22.9
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 2
19.20 scores on a scale
Interval -19.8 to 58.2
16.75 scores on a scale
Interval 11.76 to 21.75
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 3
21.00 scores on a scale
Interval -14.78 to 56.78
17.29 scores on a scale
Interval 12.46 to 22.12
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 4
29.00 scores on a scale
Interval -9.87 to 67.87
21.28 scores on a scale
Interval 15.48 to 27.09
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 5
26.20 scores on a scale
Interval -10.17 to 62.57
18.20 scores on a scale
Interval 12.69 to 23.7
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 6
26.40 scores on a scale
Interval -1.01 to 53.81
18.45 scores on a scale
Interval 13.27 to 23.63
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 7
28.75 scores on a scale
Interval -15.94 to 73.44
19.29 scores on a scale
Interval 13.46 to 25.12
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 8
27.63 scores on a scale
Interval -17.84 to 73.09
17.21 scores on a scale
Interval 11.41 to 23.02
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 9
17.00 scores on a scale
Interval -13.29 to 47.29
17.64 scores on a scale
Interval 11.58 to 23.7
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 10
19.38 scores on a scale
Interval 7.3 to 31.45
18.12 scores on a scale
Interval 12.33 to 23.91
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 11
11.50 scores on a scale
Interval 0.75 to 22.25
20.95 scores on a scale
Interval 14.57 to 27.33
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 12
19.33 scores on a scale
Interval -3.75 to 42.41
19.88 scores on a scale
Interval 13.6 to 26.16
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 13
70.00 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
16.00 scores on a scale
Interval -25.04 to 57.04
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 15
20.75 scores on a scale
Interval -2.97 to 44.47
Pain Intensity in Participants With Moderate Versus Severe Haemophilia A, as Reported by Participants Using a Visual Analogue Scale
Month 16
12.50 scores on a scale
Interval -146.33 to 171.33

SECONDARY outcome

Timeframe: Baseline and every 3 months until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=97 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants With Moderate Versus Severe Haemophilia A by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Etoricoxib
0 Participants
5 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product of Concomitant Medications Taken to Control Pain Over the Course of the Study
Paracetamol
0 Participants
4 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

The following types of regimens used to treat haemophilia A are reported here: on-demand (to stop bleeding) and prophylaxis (regular infusions of clotting factor to prevent bleeds). Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=97 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants With Moderate Versus Severe Haemophilia A by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
Prophylaxis for Haemophilia
5 Participants
97 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Type of Regimen Used for Treatment of Haemophilia A Over the Course of the Study
On Demand for Haemophilia
1 Participants
0 Participants

SECONDARY outcome

Timeframe: From baseline to study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=97 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Factor VIII, Recombinant
0 Participants
1 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Emicizumab
0 Participants
17 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Desmopressin
0 Participants
1 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Tranexamic Acid
1 Participants
1 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
On Demand; Octocog Alfa
1 Participants
0 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Octocog Alfa
1 Participants
38 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Efmoroctocog Alfa
2 Participants
23 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Moroctocog Alfa
1 Participants
7 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Turoctocog Alfa
0 Participants
8 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Lonoctocog Alfa
0 Participants
6 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Rurioctocog Alfa Pegol
0 Participants
6 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Damoctocog Alfa Pegol
0 Participants
3 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Simoctocog Alfa
1 Participants
2 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Turoctocog Alfa Pegol
0 Participants
3 Participants
Number of Participants With Moderate Versus Severe Haemophilia A by the Product Used for Treatment of Haemophilia A
Prophylaxis; Factor VIII (Antihaemophilic Factor)
0 Participants
2 Participants

SECONDARY outcome

Timeframe: From baseline to the time of switch to a new therapy (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker.

Participants could have received more than one medication.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=97 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Number of Participants With Moderate Versus Severe Haemophilia A Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Turoctocog Alfa Pegol
2 Participants
5 Participants
Number of Participants With Moderate Versus Severe Haemophilia A Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Emicizumab
0 Participants
8 Participants
Number of Participants With Moderate Versus Severe Haemophilia A Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Damoctocog Alfa Pegol
0 Participants
3 Participants
Number of Participants With Moderate Versus Severe Haemophilia A Who Switched to a New Approved Drug for Treatment of Haemophilia A by the Product Used
Rurioctocog Alfa Pegol
0 Participants
3 Participants

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoint.

The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L includes five levels of severity in each of the five EuroQol-5D dimensions and the EQ VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each dimension having 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state. EQ-5D-5L questionnaire was submitted to the participants every 3 month from baseline during the study.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=94 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 11
0.93 scores on a scale
Interval 0.85 to 1.01
0.90 scores on a scale
Interval 0.87 to 0.92
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Baseline
0.92 scores on a scale
Interval 0.84 to 1.0
0.93 scores on a scale
Interval 0.91 to 0.94
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 1
0.89 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 3
0.88 scores on a scale
Interval 0.67 to 1.09
0.90 scores on a scale
Interval 0.88 to 0.93
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 4
0.90 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
0.95 scores on a scale
Interval 0.9 to 0.99
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 5
0.94 scores on a scale
Interval 0.11 to 1.76
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 6
0.92 scores on a scale
Interval 0.79 to 1.05
0.90 scores on a scale
Interval 0.87 to 0.92
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 7
0.92 scores on a scale
Interval 0.83 to 1.01
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 8
0.91 scores on a scale
Interval 0.79 to 1.03
0.93 scores on a scale
Interval 0.9 to 0.95
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 9
0.83 scores on a scale
Interval 0.49 to 1.18
0.88 scores on a scale
Interval 0.85 to 0.91
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 10
0.80 scores on a scale
Interval 0.62 to 0.97
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 12
0.92 scores on a scale
Interval 0.89 to 0.96
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 13
0.62 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 14
0.86 scores on a scale
Interval 0.79 to 0.93
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 15
0.85 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 17
0.90 scores on a scale
Interval -0.33 to 2.14
HRQoL: EQ-5D-5L Health State Utility Index Score Over Time Moderate Versus Severe Haemophilia A
Month 18
0.92 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoint.

The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and the other section is an evaluation of the overall health status using VAS. The VAS records the respondent's self-rated health on a 20 cm vertical VAS from 0 to 100 on how good or bad their health is at assessment; 0 means the worst health imaginable, and 100 means the best health imaginable.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=94 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 1
81.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 3
81.2 scores on a scale
Interval 54.6 to 107.8
80.5 scores on a scale
Interval 76.0 to 85.1
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 8
48 scores on a scale
Interval -358.6 to 454.6
79.7 scores on a scale
Interval 72.8 to 86.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 9
82.3 scores on a scale
Interval 45.0 to 119.7
72.0 scores on a scale
Interval 60.6 to 83.5
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 11
73.5 scores on a scale
Interval 21.0 to 126.0
75.5 scores on a scale
Interval 68.5 to 82.4
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 12
69.6 scores on a scale
Interval 55.5 to 83.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 13
65.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Baseline
88.3 scores on a scale
Interval 72.9 to 103.8
81.5 scores on a scale
Interval 77.2 to 85.8
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 4
75.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
87.6 scores on a scale
Interval 74.4 to 100.7
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 5
83.5 scores on a scale
Interval -75.3 to 242.3
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 6
84.4 scores on a scale
Interval 71.8 to 97.0
75.1 scores on a scale
Interval 69.2 to 81.1
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 7
64.0 scores on a scale
Interval 29.6 to 98.4
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 10
72.5 scores on a scale
Interval 40.0 to 105.0
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 14
83.3 scores on a scale
Interval 56.7 to 109.8
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 15
75.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 17
85.0 scores on a scale
Interval -105.6 to 275.6
Health Status Measured Over Time, as Reported by Participants Using EQ-5D VAS Score in Participants With Moderate Versus Severe Haemophilia A
Month 18
97.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at given timepoints.

The HJHS is an instrument developed to measure joint health status and to identify early signs of joint disease in children. This tool assesses joints most commonly affected by bleeding (knees, ankles, and elbows). Each of the 6 joints is assessed across 8 domains (Swelling, Duration of Swelling, Atrophy, Crepitus, Flexion Loss, Extension Loss, Pain, and Strength), and a Total Score is calculated as the sum of all joint domain scores. The total score range is from 0 to 124 points (a score of 0 indicates no joint damage). A higher score indicates higher joint damage.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=96 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
HJHS Total Score for Participants With Moderate Versus Severe Haemophilia A
Baseline
8.3 scores on a scale
Interval -1.1 to 17.8
10.1 scores on a scale
Interval 7.2 to 12.9
HJHS Total Score for Participants With Moderate Versus Severe Haemophilia A
Month 6
20.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
13.3 scores on a scale
Interval 2.6 to 24.0
HJHS Total Score for Participants With Moderate Versus Severe Haemophilia A
Month 12
0.0 scores on a scale
Since only one participant was evaluated, upper and lower limit of 95% CI could not be calculated.
12.8 scores on a scale
Interval 7.6 to 17.9

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The number of days away from school or work (participant) was analyzed every month as a continuous variable. The yearly rate was derived on a per participant basis as the proportion between the total number of days away from school and/or work and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=90 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Days Away From School for Participants With Moderate Versus Severe Haemophilia A
0.0 days/year
Interval 0.0 to 5.0
0.0 days/year
Interval 0.0 to 57.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The number of days away from work was analyzed every month as a continuous variable. The yearly rate was derived on a per participant (for parents/caregivers) basis as the proportion between the total number of days away from work and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=90 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Days Away From Work for Parents/Caregivers of Participants With Moderate Versus Severe Haemophilia A
0.0 days/year
Interval 0.0 to 0.0
0 days/year
Interval 0.0 to 57.0

SECONDARY outcome

Timeframe: Baseline and every month until study completion (up to 18 months)

Population: ITT population included all enrolled participants who received the ePRO application and the fitness tracker. Overall number analyzed is the number of participants with data available for analysis.

The yearly rate was derived on a per participant basis as the proportion between the total number of hospitalization days and the duration of the study (derived as end of study date - baseline date + 1) multiplied by 365.25.

Outcome measures

Outcome measures
Measure
Standard of Care: 12-17 Years
n=6 Participants
Participants who were 12-17 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care: 18-30 Years
n=90 Participants
Participants who were 18-30 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Standard of Care:31-50 Years
Participants who were 31-50 years of age with severe or moderate Haemophilia A without inhibitors against Factor VIII receiving standard of care treatment, independently of participation in the current study, according to clinician's independent therapeutic decision were enrolled for a maximum observation period of 18 months.
Yearly Rate of Hospitalization Days for Participants With Moderate Versus Severe Haemophilia A
0 days/year
Interval 0.0 to 0.0
0 days/year
Interval 0.0 to 15.6

Adverse Events

Standard of Care for Haemophilia A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800 821 8590

Results disclosure agreements

  • Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
  • Publication restrictions are in place

Restriction type: OTHER